Kenya: U.S.$3.7 Million Allocated for Phase Two Trial of Rift Valley Fever Vaccine

[Capital FM] Nairobi — The Kenya Medical Research Institute (KEMRI) Wellcome Trust, in collaboration with the University of Oxford, is set to launch the first Phase 2 of Rift Valley Fever vaccine-ChAdOx1 RVF, in Kenya.



Source link : https://allafrica.com/stories/202410160053.html

Author :

Publish date : 2024-10-16 06:24:06

Copyright for syndicated content belongs to the linked Source.